| Institution: | 1. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) , Bethesda, MD, USA  https://orcid.org/0000-0001-9144-6558;2. Department of Medicine, MedStar Health Internal Medicine Residency Program , Baltimore, MD, USA https://orcid.org/0000-0002-1483-2241 |
| Abstract: | ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology. However, immune system overactivation from ICIs has introduced a novel medical entity known as immune-related adverse events (irAEs), that can affect any organ or tissue. ICI-induced inflammatory arthritis (ICI-IIA) is the most common musculoskeletal irAE and can lead to significant morbidity and limitation in anti-cancer therapy. |
![ORCID Icon]({"type":"image","src":"/templates/jsp/images/orcid.png"} "ORCID Icon")
https://orcid.org/0000-0001-9144-6558;2. Department of Medicine, MedStar Health Internal Medicine Residency Program , Baltimore, MD, USA